SLC5A2 and type 2 diabetes mellitus: Previous studies have observed the effect of SGLT2 inhibitors on decreasing blood pressure in patients with T2DM [26–28], consistent with our results obtained from 9 weeks of dapagliflozin treatment in HFpEF pigs.